Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.09 USD

28.09
46,845,401

-0.21 (-0.74%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $28.11 +0.02 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Glaxo (GSK) Eyes Nod for Triumeq Expanded Use in Pediatric HIV

by Zacks Equity Research

Glaxo (GSK) seeks approval for a new dispersible single-tablet regimen containing dolutegravir to treat children living with HIV.

Pfizer (PFE) Stock Moves -1.19%: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $42.42, marking a -1.19% move from the previous day.

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Is Pfizer (PFE) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BioNTech (BNTX) Begins Dosing in mRNA Cancer Vaccine Study

by Zacks Equity Research

BioNTech (BNTX) doses the first patient in a phase II study on its mRNA cancer vaccine candidate, BNT122, in patients with colorectal cancer.

3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data

by Zacks Equity Research

Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.

Kinjel Shah headshot

Vaccine Stocks Down Following Merck's COVID-19 Pill Success

by Kinjel Shah

Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19

The Zacks Analyst Blog Highlights: Barings BDC, FirstEnergy, Pfizer and Redwood Trust

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Barings BDC, FirstEnergy, Pfizer and Redwood Trust

Sweta Jaiswal, FRM headshot

Take a Look at the Top-Performing Biotech ETFs YTD

by Sweta Jaiswal, FRM

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

Tirthankar Chakraborty headshot

4 of the Best Stocks to Counter a Volatile October

by Tirthankar Chakraborty

After the September slump, more volatility may be awaiting October, which calls for investing in risk-adjusted stocks like BARINGS BDC (BBDC), FirstEnergy (FE), Pfizer (PFE) & Redwood Trust (RWT).

The Zacks Analyst Blog Highlights: Pfizer, Novo Nordisk and Sanofi

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Novo Nordisk and Sanofi

AstraZeneca (AZN) to Buy Full Stake in Rare Disease Drugmaker

by Zacks Equity Research

AstraZeneca (AZN) looks to buy full stake in Caelum Biosciences to sharpen its focus on rare-disease drugs.

Pfizer's (PFE) Prevnar 20 Plus Flu Vaccine Study Meets Goal

by Zacks Equity Research

Pfizer's (PFE) Prevnar 20 co-administered with a flu vaccine elicits non-inferior immunogenicity compared to administration of the vaccines one month apart in a late-stage study.

J&J (JNJ) Starts Phase III Study on RSV Vaccine in Older Adults

by Zacks Equity Research

J&J (JNJ) starts the phase III study on its RSV vaccine candidate in adults aged 60 years and above.

Kinjel Shah headshot

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

by Kinjel Shah

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

United Airlines (UAL) to Sack Workers on Vaccine Refusal Grounds

by Zacks Equity Research

The 593 workers of United Airlines (UAL) have not applied for exemption from getting jabbed on medical or religious grounds.

Sanghamitra Saha headshot

5 Winning Global ETFs of First Nine Months of 2021

by Sanghamitra Saha

Global markets have rallied this year on return of the risk-on sentiments. However, rising rate worries caused occasional turmoil in the market in September.

Sweta Killa headshot

5 Top ETF Stories of Nine Months of 2021

by Sweta Killa

We discuss some of the hot events of the first nine months of this year that influenced the market in a big way.

Pfizer (PFE) Submits COVID-19 Vaccine Data on Children to FDA

by Zacks Equity Research

Pfizer (PFE) and BioNTech plan to seek emergency use authorization for Comirnaty in children 5 to less than 12 years of age.

Glaxo's (GSK) Long-Acting Drug NDA Gets Priority Tag for PrEP

by Zacks Equity Research

Glaxo's (GSK) HIV subsidiary, ViiV Healthcare gets FDA's priority review for a new drug application for long-acting cabotegravir regimen. ViiV Healthcare signs a deal for developing ultra long-acting HIV treatment.

Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data

by Zacks Equity Research

Sanofi (SNY) dumps development of mRNA-based COVID vaccine despite promising data from an early study. Instead, it will focus on its adjuvanted recombinant protein vaccine candidate.

Lilly's (LLY) Erbitux Gets FDA Nod for Expanded Use in CRC

by Zacks Equity Research

Eli Lilly (LLY) secures FDA approval for Erbitux combined with Pfizer's Braftovi to treat BRAF V600E mutation-positive metastatic CRC in adult patients who received prior therapy.

PFE vs. NVO: Which Stock Is the Better Value Option?

by Zacks Equity Research

PFE vs. NVO: Which Stock Is the Better Value Option?

Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (PFE) Outperforming Other Medical Stocks This Year?

Pfizer (PFE) Begins COVID Prevention, mRNA Flu Vaccine Studies

by Zacks Equity Research

Pfizer (PFE) begins new studies on its oral antiviral pill for the prevention of COVID-19 infection and a potential mRNA influenza vaccine.